What’s up everyone, we have recently seen this $3 penny stock, Neurometrix (NURO) explode
by over 180% in the last trading day alone and over 750% in the last 5 days on the back
of FDA approval.
And what’s interesting is that Neuro is still only $95m in market cap.
NeuroMetrix Received FDA approval for their Breakthrough Device, Quell Designated for
Treatment of Fibromyalgia, with its Wearable Neurostimulation Technology.
Fibromyalgia is a common form of chronic pain that is also accompanied by fatigue, sleep,
cognitive and mood disturbances which has been huge on the back of covid lockdown stay
at home lifestyle.
It affects 5 million to 15 million people, or 2% to 6% of the U.S. population, and is
most often diagnosed in people between the ages of 30 and 50.
Quell is a non-invasive wearable neurostimulator that provides flexible and precise nerve stimulation.
So in today’s video, I’ll be sharing with you two solid biotech stocks with game changing
technology which are highly rated by analysts and have FDA approval within sight.
These top penny stocks are risky bets which haven’t been discovered by the market yet
and so have the potential to make you some massive returns.
So make sure you don’t miss out on these big bangers by liking the video and turn on
the notification bell to get these hot penny stocks instantly.
And also if you want two free stocks worth over $1800 from Webull and also where you
can buy fractional shares, please hit the link in the top comment or description below.
I would really appreciate it.
Thank you so much.
So let’s get straight into it, with our number 2 penny stock here, which is Inspira
Technologies Oxy (IINN).
It has a share price sitting at $4.81 and market cap of $36.9m.
This penny stock is newly listed, so hasn’t been discovered by the market yet.
It is up 6.6% over the last 5 days and flat on the month.
Inspira is Nasdaq Listed with an average of 594k shares traded over a 30day period and
over 7.8mm shares outstanding, of which 33.8% of the shares are held by insiders, so very
tightly held shares on this newly listed penny stock.
Inspira Technologies, is an innovative Medical Technology Company focused on the acute respiratory
care market.
The ART, Inspira’s novel technology, can address the unmet need of providing acute
respiratory treatment that prevents mechanical ventilation while patients are awake and breathing
spontaneously.
Based on sub-dynamic technology, the ART system oxygenates 1 liter of blood in a minute, within
which the patient’s oxygen saturation is boosted to a safe level of 95% or higher.
The affordability and simplicity of ART’s respiratory treatment caters to millions of
people worldwide who currently do not have access to Intensive Care Units.
The ART500 Technology is a unique alternative which has significant advantages including
patient experience, cost advantage and ease of use.
They have the Potential to lead the Early Oxygenation Market With Multiple Growth Drivers.
The respiratory care market size is estimated to reach approximately $29.86Bn by 2025.
And they have the opportunity to gain significant market share from the established players
such as Philips, Siemens and more, with ~20 million patients annually admitted to ICUs,
requiring acute respiratory care.
So really exciting stuff.
They are taking a multi-step approach to the regulatory clearance process, where they are
looking to submit the first 510(K) in Q4-2021 relating to primary sources of the ART500
with additional 510(k) filings planned for 2022.
And Additional milestones are planned for 2022 and 2023..
These milestones may seem a long way off but they have a clear plan to create strategic
partnerships, collaboration with medical device companies and strategic manufacturing agreements
which are multiple catalysts to blow its share price if all goes to plan.
There are also other risks to be aware of that, this stock will not be revenue generating
till ART500 is commercialised so until then it will be incurring R&D costs and operating
expenses.
So a key watch out with this stock.
Next up to our number 1 penny stock here, which is Electromedical Technologies Inc (EMED).
It has a share price sitting at 5.6cents and market cap of $2.88m.
So a very very tiny stock but with massive potential if you can stomach the risks with
this one.
This penny stock is down 19.8% over the last month and over the last 6months it is down
87.5% making it feel like the only way is down but the turnaround could be explosive
with its outlook and key milestones.
Electromedical is OTC QB Listed with an average of 661k shares traded over a 30day period
and over 48.7m shares outstanding.
Electromedical is a bioelectronics manufacturing company and their mission is to improve global
wellness for people suffering from various painful conditions by relieving chronic and
acute pain using energy, frequency and vibration as an alternative to pharmaceuticals.
They do this by delivering innovative solutions, providing fast and long lasting pain relief,
across the broadest range of ailments and engineer simple-to-use bioelectronics therapy
devices, which send a proprietary sequence of electrical signals.
So very similar area of focus to Neurometrix on chronic pain.
An analyst Rob Goldman recently covered this penny stock in March at 30cents and gave it
a price target of $5.7 over a 12 – 18months period.
3 months in, this penny stock is changing hands at 5.6 cents meaning a potential upside
opportunity of 100X from current levels which is extremely exciting.
And Here’s why.
They say EMED has achieved a key funding milestone which they believe de-risks the stock and
affirms their revenue forecasts and price target.
This leading, chronic pain management bioelectronics provider boasts an FDA-cleared flagship device
that has a 10,000 unit installed base.
Plus, EMED is set for clearance of a new device in early 2022 that is smaller, cheaper, and
with more capabilities including a telemedicine feature.
Targeting multiple markets, EMED’s current and future offerings are primed to serve as
an effective, and non-invasive alternative to current drugs, including the $24 billion
opioids market.
Bioelectronics is an important and developing field of “electronic” medicine which uses
safe electrical impulses over the body’s neural circuitry to relieve pain, without
drugs.
And EMED’s innovative, affordable financial model also includes a novel telemedicine feature
which, along with efficacy and ease of use, should drive new adoption.
EMED’s recurring model includes a nominal down payment and a monthly subscription fee.
Their forecasts include a conservative 80,000 POD units sold in 2022 and a 50% top-line
jump in 2023.
With an updated 12-18-month term and price target of $5.70, EMED’s shares are undervalued,
relative to its peer group.
And in their view, the recent drop in stock price from their initiation date represents
a terrific entry point for opportunistic investors.
So really exciting stuff and an explosive outlook if this company can sell sell and
sell enough of this FDA approved WellnessPro Plus products.
So a very interesting and mindblowing prospects ahead for these penny stocks but only consider
getting in if the price is right for you and if you fully understand the risks.
This video is not financial advice, a buy or a sell recommendation, but is meant to
bring some new and exciting penny stocks to your attention for you to do your own research..
As always I would love to hear from you, so please let me know your thoughts on these
top penny stocks in the comments section below and what other penny stocks are catching your
eyes lately.
And If you are new to my channel please ensure to subscribe and hit the bell so you are notified
when I upload new videos.
If you would like to see more videos like this, please check out this video right here
or this playlist right here to watch equally insightful content from the channel.
Thank you so much for being here and I look forward to have you in my next video.
Thank you